Zimmer Biomet Q3 sales beat estimates, raises FY outlook

What happened

Zimmer Biomet said third-quarter net sales rose 3.1% year over year, slightly beating analyst expectations. Adjusted earnings per share, meaning profit per share excluding certain items, were flat year over year and beat expectations. The company raised its full-year 2026 sales-growth and adjusted earnings outlook.

Confirmed

Global impact / market context

Higher guidance signals that management expects sales growth and adjusted profit per share to improve beyond its earlier forecast. If that outlook is achieved, stronger revenue from several product areas could support earnings, while the results also suggest the company’s commercial efforts are contributing to performance.

Analyst inference

The reported sales increase was modest, and adjusted earnings per share were unchanged from a year earlier, despite both measures exceeding analyst estimates. The raised outlook is therefore a more forward-looking signal than the quarterly beat, but it remains a company forecast rather than a realized result.

Analyst inference

What to watch

1. Check whether future quarterly reports show sales growth across hips, surgical equipment and technology, bone cement, and surgical products, the areas cited as supporting results. Analyst inference
2. Compare reported 2026 organic constant-currency sales growth with the new 3.0%–3.5% forecast; this measure removes currency changes and some other effects. Confirmed
3. Watch whether adjusted diluted earnings per share reaches the revised $8.50–$8.60 range, since falling short would weaken the raised full-year profit outlook. Confirmed

Evidence

• Original source link unavailable